Budesonide MMX in the treatment of ulcerative colitis

Česká verzia

Authors: Falt Přemysl
Authors place of work: II. interní klinika – gastroenterologická a geriatrická LF UP a FN Olomouc a II. interní gastroenterologická klinika LF UK v Hradci Králové
Published in the journal: Gastroent Hepatol 2020; 74(3): 246-249
Category: IBD: Case Report
doi: https://doi.org/10.14735/amgh2020246

Summary

Budesonide MMX is a novel formulation with extended release of the drug throughout the colon. Budesonide MMX is indicated for the induction of remission in patients with mild to moderate active ulcerative colitis where mesalamine treatment was not sufficient or tolerated. Thanks to low systemic availability, the treatment is not associated with traditional complications of glucocorticoid treatment and its safety profile is comparable to placebo. Limited data suggest that budesonide MMX may be effective for long-term maintenance treatment in selected patients.

Keywords:

Ulcerative colitis – budesonide – MMX

Zdroje

1. Overview of budesonide therapy for adults with inflammatory bowel disease. [online]. Available from: www.uptodate.com/contents/overview-of-budesonide-therapy-for-adults-with-inflammatory bowel-disease.

2. Torres J, Bonovas S, Doherty G et al. ECCO Guidelines on therapeutics in Crohn‘s disease: medical treatment. J Crohns Colitis 2020; 14 (1): 4–22. doi: 10.1093/ecco-jcc/jjz180.

3. Harbord M, Eliakim R, Bettenworth D et al.Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017; 11 (7): 769–784. doi: 10.1093/ecco-jcc/jjx009.

4. Brunner M, Ziegler S, Di Stefano AF et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol 2006; 61 (1): 31–38. doi: 10.1111/j.1365-2125.2005.02517.x.

5. Sandborn WJ, Travis S, Moro L et al. Once-daily budesonide MMX (R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143 (5): 1218–1226 e1212. doi: 10.1053/j.gastro.2012.08.003.

6. Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63 (3): 433–441. doi: 10.1136/gutjnl-2012-304258.

7. Sandborn WJ, Danese S, Ballard ED. Efficacy of Budesonide MMX 6 mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology 2012; 142 (5 Suppl 1): 564.

8. Rubin DT, Cohen RD, Sandborn WJ et al. Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: a randomised, placebo-controlled trial. J Crohns Colitis 2017; 11 (7): 785–791. doi: 10.1093/ecco-jcc/jjx032.

9. Danese S, Hart A, Dignass A et al. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX (R) (Cortiment (R) (MMX (R))) for active, mild-to-moderate ulcerative colitis. United European Gastroenterol J 2019; 7 (9): 1171–1182. doi: 10.1177/20506406 19864848.

10. Rydzewska G, Paridaens K, Danese S et al. Assessment of Budesonide MMX effectiveness for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the prospective multi-center observational study CORE Practice. In: UEG Week. Barcelona, Spain 2019.

11. Hrdlička L, Bortlík M, Douda T et al. Použití budesonide MMX (Cortiment 9 mg) v léčbě ulcerózní kolitidy – data z reálné praxe. Gastroenterol Hepatol 2016; 70 (6): 509–513.

12. Hrdlička L, Bortlík M, Douda T et al. Efektivita a bezpečnost budesonidu MMX (Cortiment) v dlouhodobé udržovací léčbě ulcerózní kolitidy. Gastroenterol Hepatol 2018; 72 (4): 329–333.

13. Sherlock ME, MacDonald JK, Griffiths AM et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2015; (10): CD007698. doi: 10.1002/14651858.CD007698.pub3.

14. D‘Haens GR, Kovacs A, Vergauwe P et al. Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX (R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010; 4 (2): 153–160. doi: 10.1016/j.crohns.2009.09.007.

15. Sandborn WJ, Danese S, D‘Haens Get al. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther 2015; 41 (5): 409–418. doi: 10.1111/apt.13076.

16. Travis S, Danese S, David Ballard E et al. Su2088 Safety analysis of budesonide MMX 6 mg used for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology 2012; 142 (Suppl 1): S566–S567.

17. van der Woude CJ, Ardizzone S, Bengtson MB et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015; 9 (2): 107–124. doi: 10.1093/ecco-jcc/jju006.

18. SPC Cortiment 9 mg. [online]. Dostupné z: https: //pribalovy-letak.info/cortiment-9- mg/ souhrn.

19. Shor J, Churrango G, Hosseini N et al. Management of microscopic colitis: challenges and solutions. Clin Exp Gastroenterol 2019; 12: 111–120. doi: 10.2147/CEG.S165047.

20. Kamboj AK, Cotter TG, Hicks SB et al. Extended-release multimatrix Budesonide for microscopic colitis. Inflamm Bowel Dis 2017; 23 (5): E21–E22. doi: 10.1097/MIB.0000000000001090.

21. Singh N, Patel A. Novel use of budesonide MMX in the treatment of lymphocytic colitis. J Gastrointest Dig Syst 2016; 6 (2): 1–3. doi: 10.4172/2161-069X.1000423.